Enhanced Bio-Orthogonal Drug Activation System

This invention improves the bio-orthogonal drug activation system by enhancing the stability of the dienophile in physiological conditions, accelerating the retro Diels-Alder reaction, and providing targeted delivery of the prodrug.

The original patent disclosed a bio-orthogonal drug activation system based on the retro Diels-Alder reaction. However, the system had limitations, such as the instability of the dienophile in physiological conditions, slow reaction kinetics, and lack of targeted delivery. This new inventive concept addresses these limitations by modifying the dienophile to enhance its stability, accelerating the reaction with an external stimulus, and conjugating the prodrug to a targeting moiety.

The new system comprises a trans-cyclooctene derivative satisfying formula (1a) and a diene activator, wherein the dienophile and diene activator react to release the drug via a retro Diels-Alder reaction. The dienophile is modified to enhance its stability in physiological conditions, and the diene activator can be encapsulated in a nanoparticle for targeted delivery. Additionally, the retro Diels-Alder reaction can be accelerated by an external stimulus, such as heat or light, to improve the efficiency of the system.

The new claims introduce several novel features, including the modification of the dienophile to enhance its stability, the use of nanoparticle-encapsulated diene activators, and the acceleration of the retro Diels-Alder reaction by an external stimulus. These features provide a significant improvement over the original patent and demonstrate a non-obvious inventive step.

Alternative embodiments of the inventive concept include the use of different dienophile modifications, various nanoparticle compositions, and different external stimuli to accelerate the reaction. Additionally, the system can be adapted for use with different prodrugs and targeting moieties to expand its therapeutic applications.

The enhanced bio-orthogonal drug activation system has significant commercial potential in the pharmaceutical industry, particularly in the areas of targeted cancer therapy and precision medicine. The system's ability to provide efficient and targeted delivery of prodrugs could lead to improved treatment outcomes and reduced side effects, making it an attractive solution for pharmaceutical companies and researchers.